You just read:

Phase III Study of Dabigatran Etexilate Mesylate Met Primary Endpoint for Six-Month Treatment of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE)

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Dec 17, 2013, 08:00 ET